Combination chemotherapy as an adjuvant treatment in operable breast cancer

G. Bonadonna, E. Brusamolino, P. Valagussa, A. Rossi, L. Brugnatelli, C. Brambilla, M. De Lena, G. Tancini, E. Bajetta, R. Musumeci, U. Veronesi

Research output: Contribution to journalArticlepeer-review


Prolonged cyclic combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil was evaluated as adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph nodes. After 27 months of study, treatment failure occurred in 24 per cent of 179 control patients and in 5.3 per cent of 207 women given combination chemotherapy (P-6), the advantage appearing statistically significant in all subgroups of patients. Patients with four or more positive axillary nodes had a higher per cent of relapses than those with fewer nodes. The initial new clinical manifestations occurred in distant sites in 81.5 per cent of relapsed patients. Long term chemotherapy produced an acceptable toxicity, thus allowing the administration of a high percentage of drug dosage. These results should be considered with caution, since, at present, the effect of this therapy on survival and possible long term side effects remain unknown.

Original languageEnglish
Pages (from-to)405-410
Number of pages6
JournalNew England Journal of Medicine
Issue number8
Publication statusPublished - 1976

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Combination chemotherapy as an adjuvant treatment in operable breast cancer'. Together they form a unique fingerprint.

Cite this